TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03885089

Intervention type: DRUG
Intervention: Infliximab [infliximab biosimilar 3]
Description: \<Psoriasis\> The usual dose is 5 mg as Infliximab (Genetical Recombination) \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
Study: NCT02732340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: triple-branched stent graft
Description: place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
Study: NCT03694041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAD: APX-115
Description: Drug: APX-115 SAD APX-115 SAD for 1day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAD: Placebo
Description: Drug: Placebo Placebo for 1day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD: APX-115
Description: Drug: APX-115 MAD APX-115 MAD repeatedly administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAD: Placebo
Description: Matching study drug will be repeatedly administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food effect: fasted and fed
Description: A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food effect: fasted and fed
Description: A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Metabolic probe with or without APX-115
Description: A metabolic probe will be administered with and without APX-115.
Study: NCT03337152

Intervention type: DRUG
Group type: OTHER
Intervention: primaquine
Description: Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.

Intervention type: DRUG
Group type: OTHER
Intervention: chloroquine + primaquine
Description: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
Study: NCT00656734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX 1411
Description: MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
Study: NCT02288065

Intervention type: DRUG
Intervention: sterile talc pleurodesis
Description: medical thoracoscopy and talc pleurodesis. No specific device is studied.

Intervention type: DRUG
Intervention: sterile talc pleurodesis
Description: medical thoracoscopy and talc pleurodesis. No specific device is studied.
Study: NCT00004992

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02612441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real Acupuncture Needles
Description: Acupuncture needles

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Acupuncture Needles
Description: sham Acupuncture Needles
Study: NCT03004469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-3074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P-3074 Vehicle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-3074 Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finasteride Placebo
Study: NCT03498287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Device
Description: Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). \*Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
Study: NCT02580994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion at the dose of 200 mg on day 1 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cis/carboplatin and etoposide
Description: Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis/carboplatin and etoposide
Description: Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
Study: NCT02542436

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study: NCT01566240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
Study: NCT02229630

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pregnant women with intra-uterine growth restricted Foetuses
Description: Diffusion-weighted cerebral MRI before 32 weeks of gestation
Study: NCT02757781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community of Practice
Description: The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
Study: NCT04408118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15.~The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Will be administered intravenously over 30-90 minutes on Days 1 and 15.
Study: NCT02227108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox
Description: Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
Study: NCT04580823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting with exogenous ketone salt supplement
Description: Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-Prandial with exogenous ketone salt supplement
Description: Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan and they will have a liquid meal 20 minutes before the scan.
Study: NCT01458314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily NIV during rehabilitation
Description: Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
Study: NCT04322578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 250mg po bid. Savolitinib 300mg po, qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500mg/m2, ivgtt erery 21day.
Study: NCT01382745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200mg Nimotuzumab once a week for 12 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
Study: NCT03762499

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography scan
Description: Non-invasive ultrasound imaging of the heart.
Study: NCT00183885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin-c, cisplatin
Description: Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
Study: NCT00673933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL) PDT
Description: Cream application followed by illumination with red light

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methyl aminolevulinate (MAL) PDT
Description: Cream application followed by illumination with red light
Study: NCT00930254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV puncture guided by ultrasound
Description: Comparisons between traditional and ultrasound group
Study: NCT00369382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine or tacrolimus
Description: Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
Study: NCT01458314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation without NIV
Description: Training in patients without NIV adoption
Study: NCT02719470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIRT
Description: MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIRT
Description: MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIRT
Description: MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIRT
Description: MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
Study: NCT00456495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Subconjunctival injection of drug every 2 to 4 weeks
Study: NCT01631513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucynta ER
Description: 100 to 250 mg every 12 hours
Study: NCT01946074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered by intravenous infusion.
Study: NCT02719470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIRT
Description: MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
Study: NCT00917306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Gel
Description: 0.05% two day treatment
Study: NCT02066194

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Electroacupuncture
Study: NCT03623282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synatura® 15 mL
Description: All subjects will receive Synatura® 15 mL every day three times for 3 months.
Study: NCT03415763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
Study: NCT01946074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: 5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
Study: NCT03209778

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients with Schizophrenia
Description: Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
Study: NCT03415763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 or CAPOX
Description: According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
Study: NCT02102984

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: covered biliary stents
Description: endoscopic placement of covered biliary stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncovered biliary stents
Description: endoscopic placement of uncovered biliary stents
Study: NCT03348241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Gum acacia, also known as Gum Arabic is exuded from acacia trees; mainly from Acacia Senegal (gum Hashab or Kordofan gum) which was used in this study.

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle counseling
Description: Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
Study: NCT00946569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ39758979
Description: Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo once daily orally for 12 weeks.
Study: NCT04567446

Intervention type: OTHER
Intervention: Stool
Description: collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Study: NCT01946074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-165
Description: ABT-165 will be administered by intravenous infusion at escalating dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-165
Description: ABT-165 will be administered by intravenous infusion at escalating dose levels.
Study: NCT04567446

Intervention type: OTHER
Intervention: Stool
Description: collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment

Intervention type: OTHER
Intervention: Stool
Description: collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment

Intervention type: OTHER
Intervention: Blood sample
Description: 20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment

Intervention type: OTHER
Intervention: Blood sample
Description: 20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment

Intervention type: OTHER
Intervention: Blood sample
Description: 20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Study: NCT03209778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with Schizophrenia
Description: Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
Study: NCT01946074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-165
Description: ABT-165 will be administered by intravenous infusion at escalating dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-165
Description: ABT-165 will be administered by intravenous infusion at escalating dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-165
Description: ABT-165 will be administered by intravenous infusion at escalating dose levels.
Study: NCT00238303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study: NCT02552797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making tool
Study: NCT00238303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery to remove tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery to remove tumor
Study: NCT04307836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal Denervation: DENEX system
Study: NCT01933750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PresVIEW Device Implantation
Study: NCT01529385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mild compression diabetic sock
Description: A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard diabetic sock
Description: A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
Study: NCT04246593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Market program implementation
Description: Mobile Market program implementation includes utilizing a Veggie Van model which sells reduced cost locally-grown produce in communities with barriers to accessing fresh F\&Vs because of availability, cost, or lack of produce preparation skills.The Veggie Van visits sites that already serve the target market (e.g., lower-income housing communities, community health centers, community colleges). While Mobile Market programs vary in their model and operation, we believe that the three components of Veggie Van's success are it's share model, price reductions (incentives), and educational component
Study: NCT01995136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution 0.004%
Description: benzalkonium chloride (BAC) free